Combined inhibition of mTOR and EGFR with everolimus (RAD001) and gefitinib in patients with non-small cell lung cancer who have smoked cigarettes: A phase II trial

被引：0
|
作者：
Kris, M. G. [1 ]
Riely, G. J. [1 ]
Azzoli, C. G. [1 ]
Heelan, R. T. [1 ]
Krug, L. M. [1 ]
Pao, W. [1 ]
Milton, D. T. [1 ]
Moore, E. [1 ]
Rizvi, N. A. [1 ]
Miller, V. A. [1 ]
机构：
[1] Memor Sloan Kettering Canc Ctr, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7575
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Phase II Study of Gefitinib Readministration in Patients with Advanced Non-Small Cell Lung Cancer and Previous Response to Gefitinib
    Asahina, Hajime
    Oizumi, Satoshi
    Inoue, Akira
    Kinoshita, Ichiro
    Ishida, Takashi
    Fujita, Yuka
    Sukoh, Noriaki
    Harada, Masao
    Maemondo, Makoto
    Saijo, Yasuo
    Dosaka-Akita, Hirotoshi
    Isobe, Hiroshi
    Nukiwa, Toshihiro
    Nishimura, Masaharu
    ONCOLOGY, 2010, 79 (5-6) : 423 - 429
  • [32] A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test
    Moon Ki Choi
    Jung Yong Hong
    Won Jin Chang
    Moon Jin Kim
    Sung Min Kim
    Hyun Ae Jung
    In-Gu Do
    Yoon-la Choi
    Jong-Mu Sun
    Jin Seok Ahn
    Keunchil Park
    Myung-Ju Ahn
    Cancer Chemotherapy and Pharmacology, 2015, 75 : 1229 - 1236
  • [33] Phase II trial of RAD001 in renal cell carcinoma patients with non-clear cell histology.
    Koh, Youngil
    Kim, Ji Yeon
    Lim, Ho Yeong
    Ahn, Jin-Hee
    Lee, Jae-Lyun
    Rha, Sun Young
    Kim, YuJung
    Kim, Tae Min
    Lee, Se-Hoon
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [34] A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC)
    Kim, Se Hyun
    Shim, Hyo Sup
    Cho, Jaeho
    Jeong, Jae Heon
    Kim, Sun Mi
    Hong, Yun Kyoung
    Sung, Ji Hee
    Ha, Sang-Jun
    Kim, Hye Ryun
    Chang, Hyun
    Kim, Joo Hang
    Tania, Crombet
    Cho, Byoung Chul
    LUNG CANCER, 2013, 79 (03) : 270 - 275
  • [35] A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC).
    Kim, Han Sang
    Cho, Byoung Chul
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [36] mTORC1 inhibitor RAD001 (everolimus) enhances non-small cell lung cancer cell radiosensitivity in vitro via suppressing epithelial–mesenchymal transition
    Yu Chen
    Wen-wen LI
    Ping Peng
    Wei-heng Zhao
    Yi-jun Tian
    Yu Huang
    Shu Xia
    Yuan Chen
    Acta Pharmacologica Sinica, 2019, 40 : 1085 - 1094
  • [37] Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations
    Uchibori, Ken
    Satouchi, Miyako
    Sueoka-Aragane, Naoko
    Urata, Yoshiko
    Sato, Akemi
    Imamura, Fumio
    Inoue, Takako
    Tachihara, Motoko
    Kobayashi, Kazuyuki
    Katakami, Nobuyuki
    Kokan, Chiyuki
    Hirashima, Tomonori
    Iwanaga, Kentaro
    Mori, Masahide
    Aoe, Keisuke
    Morita, Satoshi
    Negoro, Shunichi
    LUNG CANCER, 2018, 124 : 65 - 70
  • [38] Gefitinib: Phase II and III results in advanced non-small cell lung cancer
    Kelly, K
    Averbuch, S
    SEMINARS IN ONCOLOGY, 2004, 31 (01) : 93 - 99
  • [39] A phase II trial of biweekly docetaxel combined with carboplatin for patients with advanced non-small cell lung cancer
    Ishimoto, O
    Sugawara, S
    Inoue, A
    Ishida, T
    Koinumaru, S
    Hasegawa, Y
    Suzuki, T
    Miki, H
    Saijo, Y
    Nukiwa, T
    LUNG CANCER, 2005, 49 : S391 - S391
  • [40] CLINICAL EXPERIENCE USE GEFITINIB IN PATIENTS WITH NON-SMALL CELL LUNG CANCER WITH A MUTATION EGFR
    Vozniy, Eduard
    Popov, Anatoly
    Galkin, Michail
    Astrakhankina, Tamara
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1214 - S1214
12345